Annovis Bio, Inc.

NYSE:ANVS

Biotechnology

Healthcare
$1.21 +0.00%

+$0.00 today

Market cap
$51.64M
Beta
1.24
P/E (TTM)
-1.1
EPS (TTM)
-$1.47
52W Low $1.54High $5.50

Volume 1.35M

Average 1.08M

ANVS Account Payables

Amounts the company owes suppliers for goods and services received.

Annovis Bio, Inc.NYSE: ANVS

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 285.0% from a year ago

Account payables stood at $5.28M at the end of Q1 FY2026, up 285.0% from a year earlier and up 103.6% from the prior quarter. Over 3 fiscal years it compounded at -13.2% a year.

Context

  • Account payables amounted to 32.5% of total assets at the end of Q1 FY2026, up 27.4 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +285.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.28M+103.6% QoQ
Last fiscal yearDec 2025
$2.59M+12.3% YoY
Year agoMar 2025
$1.37M+285.0% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+285.0%——
1 year+12.3%——
3-year CAGR-13.2%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
2.59M USD
Year-over-year change
+12.3%
4-year CAGR
+39.3%

Account Payables vs competitors

How ANVS compares with its peers on the latest reported figures

  • ANVS's Mar 2026 account payables of $5.28M is the 3rd highest of the 6 companies compared; the peer median is $3.65M.
  • Its year-over-year change of +285.0% is the highest of 6, against a peer median of +13.4%.
  • Account payables amounts to 32.5% of total assets for ANVS, versus a peer median of 14.8%.
ANVS Competitors Peer median
Account Payables for ANVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CELUCelularity Inc.Dec 2025$26.42M +13.4%+65.7%24.6%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$8.51M +10.4%—21.2%
ANVSAnnovis Bio, Inc.Mar 2026$5.28M +285.0%-13.2%32.5%
PDSBPDS Biotechnology CorporationMar 2026$3.65M +27.7%+43.1%14.8%
MAIAMAIA Biotechnology, Inc.Mar 2026$2.98M +62.0%+20.5%8.4%
PYPDPolyPid Ltd.Mar 2026$1.54M -23.9%+35.8%8.0%
Peer median (excluding ANVS) $3.65M+13.4%+39.4%14.8%

Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents45.69M28.38M5.75M10.55M19.53M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets9.87K7.54M20.8K7.5K7.5K
Total Current Assets46M36.02M10.21M13.93M21.08M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets00000
Total Assets46M36.02M10.21M13.93M21.08M
Account Payables688.07K3.96M1.29M2.31M2.59M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities105.67K02731.21M618.66K
Total Current Liabilities1.51M7.7M4.28M3.88M3.64M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0013.68M737K595K
Total Non-current Liabilities0013.68M737K595K
Total Liabilities1.51M7.7M17.96M4.62M4.23M
Common Stock8108161.05K1.41K2.72K
Retained Earnings(28.73M)(54.05M)(110.26M)(134.85M)(163.7M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity44.49M28.32M(7.75M)9.31M16.85M
Total Debt00000
Net Debt(45.69M)(28.38M)(5.75M)(10.55M)(19.53M)

Annovis Bio, Inc.

NYSE:ANVS

Intrinsic Alpha fair value

Locked

Current Price

$1.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.